menu
    • menu
    [{"orgOrder":0,"company":"Gabather","sponsor":"Centre for Neuropsychiatric Schizophrenia Research","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Centre for Neuropsychiatric Schizophrenia Research"},{"orgOrder":0,"company":"Gabather","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-002","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gabather","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gabather \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gabather \/ Inapplicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gabather

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            Gabather

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-002

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Centre for Neuropsychiatric Schizophrenia Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gabather Partners with Danish Center to Conduct Phase 2 Study of GT-002 for Schizophrenia

                            Details : The collaboration aims to support the clinical advancement of GT-002, which is a small molecule GABAA receptor-positive allosteric Modulator. Currently, it is being evaluated for schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : GT-002

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Centre for Neuropsychiatric Schizophrenia Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gabather

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            Gabather

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-002

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gabather reports Initial Positive Results from the EEG/fMRI Target Engagement Study

                            Details : GT-002 is an oral small molecule GABAA receptor PAM eliciting both tonic and phasic inhibitory currents. It restores ketamine induced cognitive deficits in patients with schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : GT-002

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dicot

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            Dicot

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LIB-01

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Trial of LIB-01 in Healthy Participants.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 21, 2024

                            Lead Product(s) : LIB-01

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orexo

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            Orexo

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orexo's Flagship Pharmaceutical Pipeline Asset OX124 Enters Pivotal Trial

                            Details : OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 16, 2021

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orexo

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            Orexo

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalmefene Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose R...

                            Details : The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene intramuscular injection...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : Nalmefene Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Janssen (China) Research & Development Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 23, 2017

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Janssen (China) Research & Development Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Bioequivalence Study Between Two Nicotine Replacement Therapies in Adult Healthy Smokers Motivated to Quit.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            April 26, 2017

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Exploratory Study Comparing Two Nicotine Inhalers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            November 23, 2011

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed

                            McNeil AB

                            Sweden arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 24, 2011

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth